Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis

BACKGROUND: In recent years, many important advances have been seen in anticoagulation therapy. However, bleeding risk is still a major concern. Factor XI (FXI) inhibition has emerged as a potential advantageous target to minimize this risk. OBJECTIVES: We conducted a systematic review and meta‐anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Presume, João, Ferreira, Jorge, Ribeiras, Regina, Mendes, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
THROMBOSIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828034/
https://www.ncbi.nlm.nih.gov/pubmed/36128769
http://dx.doi.org/10.1111/jth.15890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828034/
https://www.ncbi.nlm.nih.gov/pubmed/36128769
http://dx.doi.org/10.1111/jth.15890

Ejemplares similares